Healthcare
17 evidence matches
Impact 100% Confidence 90%
Health
Medicaid
Health
HR 1839 - 116Medicaid Services Investment and Accountability Act of 2019
Became Public Law No: 116-16.
Bill Text Stats
Bill text analysis is not available for this record yet.
Affected Sectors
How to read this
Sectors are deterministic matches from official Congress.gov data and cached bill text. They are source-derived signals, not conclusions about intent or economic effect.
Evidence matches count official fields, normalized subjects, cached text snippets, or extracted entities that matched the sector rules.
Impact is a bill-level rollup used for sorting and filtering. It is not an economic impact estimate.
Confidence is the strongest individual match score behind that sector.
Evidence snippets show why a sector matched and can repeat when Congress.gov repeats the same phrase across official fields.
CBO Cost Estimates
Official Congressional Budget Office cost estimate links associated with this bill through Congress.gov records.
How to read this
CBO estimates are official source documents with their own assumptions, scope, and publication dates. They can score a bill, a version of a bill, or a broader legislative package.
LawLinter stores the source link from Congress.gov and does not replace the CBO document. Use these cards as pointers for source review, not as independent fiscal advice.
CBO context shows source-attributed Congressional Budget Office cost estimates linked from official Congress.gov bill records. It is research context only; read the official CBO source document for assumptions, scope, and dates.
Campaign Finance Context
Related FEC/OpenFEC campaign-finance records for lawmakers and candidates tied to this bill through source-attributed legislative relationships. These are not donations to the bill itself.
How to read this
Amounts shown here are campaign-finance totals for sponsor or cosponsor-linked candidates and their committees in the displayed FEC cycle.
They are not donations to this bill, spending on this bill, or proof that money influenced or caused sponsorship, cosponsorship, votes, or legislative outcomes.
If multiple linked lawmakers have FEC records, this section can show multiple candidate cards and separate sponsor/cosponsor rollups.
Campaign-finance context uses source-attributed FEC/OpenFEC records that are related or relevant to the displayed bill, lawmaker, candidate, committee, or legislative relationship through deterministic links. It is research context only, not proof of influence, causation, endorsement, or that money caused a sponsorship, vote, or legislative outcome.
No FEC/OpenFEC campaign-finance context is currently linked for this bill.
Lobbying Context
Related LDA.gov filings where public lobbying activity descriptions reference this bill. These records are source-attributed research context, not evidence of influence or causation.
How to read this
LDA filings are public lobbying disclosure records. LawLinter links them here only when the filing activity text contains an exact-looking reference to this bill.
A filing can mention many issues, clients, agencies, or bills. A match should be treated as a pointer for review, not as a conclusion about why legislation changed or how any lawmaker acted.
Lobbying context uses source-attributed LDA.gov records that appear related to this bill through bill references in public lobbying activity descriptions. It is research context only, not proof of influence, causation, endorsement, lobbying effectiveness, or legislative intent.
No LDA.gov lobbying disclosure context is currently linked for this bill.
Summary
49 Public Law Mar 25, 2020
Medicaid Services Investment and Accountability Act of 2019 This bill alters several Medicaid programs and funding provisions. (Sec. 2) The bill temporarily extends the applicability of Medicaid eligibility criteria that protect against spousal impoverishment for recipients of home- and community-based services. (Sec. 3) The bill also establishes a state Medicaid option to provide for medical assistance with respect to coordinated care provided through a health home (i.e., a designated provider or team of health-care professionals) for children with medically complex conditions. States must determine payment methodologies in accordance with specified requirements; payments also temporarily qualify for an enhanced federal matching rate. (Sec. 4) The bill also temporarily extends the Medicaid demonstration program for certified community behavioral health clinics. (Sec. 5) The bill increases funding available to the Money Follows the Person Rebalancing Demonstration Program. (Under this program, the Centers for Medicare & Medicaid Services may award grants to state Medicaid programs to assist states in increasing the use of home and community care for long-term care and decreasing the use of institutional care.) (Sec. 6) Further, drug manufacturers with Medicaid rebate agreements for covered outpatient drugs must disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).
00 Introduced in House Apr 10, 2019
Medicaid Services Investment and Accountability Act of 2019 This bill alters several Medicaid programs and funding provisions. For example, the bill temporarily extends the applicability of Medicaid eligibility criteria that protect against spousal impoverishment for recipients of home- and community-based services. The bill also establishes a state Medicaid option to provide for medical assistance with respect to coordinated care provided through a health home (i.e., a designated provider or team of health-care professionals) for children with medically complex conditions. States must determine payment methodologies in accordance with specified requirements; payments also temporarily qualify for an enhanced federal matching rate. Further, drug manufacturers with Medicaid rebate agreements for covered outpatient drugs must disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).
Sponsors
Website
N/A
Phone
N/A
Office
N/A
KS
Website
N/A
Phone
N/A
Office
N/A
FU
Website
N/A
Phone
N/A
Office
N/A
![Rep. Bilirakis, Gus M. [R-FL-12]](https://www.congress.gov/img/member/117_rp_fl_12_bilirakis_gus_200.jpg)
![Rep. Dingell, Debbie [D-MI-6]](https://www.congress.gov/img/member/d000624_200.jpg)
![Rep. Guthrie, Brett [R-KY-2]](https://www.congress.gov/img/member/g000558_200.jpg)
VT
Website
N/A
Phone
N/A
Office
N/A
Timeline
Apr 18, 2019
Signed by President.
Apr 18, 2019
Signed by President.
Apr 18, 2019
Became Public Law No: 116-16.
Apr 18, 2019
Became Public Law No: 116-16.
Apr 10, 2019
Sponsor introductory remarks on measure. (CR H3224)
Apr 10, 2019
Presented to President.
Apr 10, 2019
Presented to President.
Apr 3, 2019
Message on Senate action sent to the House.
Apr 2, 2019
Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.(consideration: CR S2203)
Apr 2, 2019
Passed Senate without amendment by Voice Vote. (consideration: CR S2203)
Mar 26, 2019
Received in the Senate, read twice.
Mar 25, 2019
Mr. Ruiz moved to suspend the rules and pass the bill, as amended.
Mar 25, 2019
Considered under suspension of the rules. (consideration: CR H2773-2780)
Mar 25, 2019
DEBATE - The House proceeded with forty minutes of debate on H.R. 1839.
Mar 25, 2019
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Burgess objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
Mar 25, 2019
Considered as unfinished business. (consideration: CR H2781)
Mar 25, 2019
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H2773-2776)
Mar 25, 2019
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H2773-2776)
Mar 25, 2019
Motion to reconsider laid on the table Agreed to without objection.
Mar 22, 2019
Referred to the Subcommittee on Health.
Mar 21, 2019
Introduced in House
Mar 21, 2019
Introduced in House
Mar 21, 2019
Referred to the House Committee on Energy and Commerce.
House Votes
No House roll call votes have been linked to this bill yet.
Amendments
No amendment records are currently available for this bill.
Compiled bill record. Bill pages combine Congress.gov source payloads, normalized relationships, cached text analysis, vote links, and deterministic sector/signal extraction. This is not an official government record or legal advice; use the official source link when accuracy matters.